Opus Genetics, Inc. Assets, Fair Value Disclosure
Opus Genetics, Inc. (IRD) had Assets, Fair Value Disclosure of $3.00 million as of 2019-12-31, per its 10-Q filed 2020-10-29.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:AssetsFairValueDisclosure · last filed 2020-10-29
- 2019-12-31: Assets, Fair Value Disclosure $3.00M.
- 2019-09-30: Assets, Fair Value Disclosure $5.98M.
- 2019-06-30: Assets, Fair Value Disclosure $8.95M.
- 2019-03-31: Assets, Fair Value Disclosure $11.89M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2019-12-31 | $3.00M 10-Q · filed 2020-10-29 |
| 2019-09-30 | $5.98M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $8.95M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $11.89M 10-Q · filed 2019-05-10 |
| 2018-03-31 | $14.88M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $17.93M 10-K · filed 2019-03-07 |
| 2017-09-30 | $14.98M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $17.99M 10-Q · filed 2017-08-04 |
| 2017-03-31 | $8.02M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $8.74M 10-K · filed 2018-03-09 |
| 2016-09-30 | $13.42M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $11.52M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $14.01M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $13.24M 10-K · filed 2017-02-24 |
| 2015-09-30 | $9.01M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $16.01M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $18.66M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $22.87M 10-K · filed 2016-03-14 |
| 2014-09-30 | $20.65M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $178.16K 10-Q · filed 2014-08-13 |
| 2014-03-31 | $263.53K 10-Q · filed 2014-05-14 |
| 2013-12-31 | $296.13K 10-K · filed 2015-03-16 |
| 2013-09-30 | $609.18K 10-Q · filed 2013-11-13 |
| 2013-06-30 | $668.88K 10-Q · filed 2013-08-12 |
| 2013-03-31 | $1.06M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $1.19M 10-K · filed 2014-03-21 |
| 2012-09-30 | $317.17K 10-Q · filed 2012-11-08 |
| 2012-06-30 | $863.89K 10-Q · filed 2012-08-08 |
| 2011-12-31 | $3.38M 10-K · filed 2013-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |